Marisa Wexler, MS, senior science writer —

Abnormal buildup of iron in the lungs can cause lung fibrosis (scarring), and targeting this accumulation could be a therapeutic strategy for people with pulmonary fibrosis, a new study suggests. The study, “Critical role for iron accumulation in the pathogenesis of fibrotic lung disease,” was published in …

COVID-19 has been reported to cause lung fibrosis in some people, but the type of fibrosis that develops is distinct from what generally occurs in those with interstitial lung disease (ILD), according to a press release issued by the Pulmonary Fibrosis Foundation (PFF). COVID-19 (coronavirus disease 2019)…

Engineered models of the lung and trachea replicate the cellular dynamics found in living organisms better than other models used to study these cells in culture, a new study suggests. These engineered artificial lungs and tracheas may be more suitable to study cell-based therapies for lung diseases like pulmonary fibrosis,…

Ofev (nintedanib) limits the decline in lung function in people with idiopathic pulmonary fibrosis (IPF), regardless of the degree of impairment in gas exchange in their lungs, a study suggests. According to the researchers in the study, “these data support the use of [Ofev] in patients with IPF…

Inhaling secretions produced by lung stem cells could be therapeutically beneficial for those with idiopathic pulmonary fibrosis (IPF), a preclinical study has suggested. The study, “Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis,” was published in the journal Nature…

ART-123 (thrombomodulin alfa) failed to prolong the survival of patients with idiopathic pulmonary fibrosis (IPF) who have acute exacerbations, a study found. The study, “Thrombomodulin alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Randomized, Double-blind, Placebo-controlled Trial,” was published in the American…

Hepion Pharmaceuticals‘ CRV431 lowers the production of fibrosis-associated proteins in a variety of cell types, including lung cells, new data from the company show. CRV431 is a small molecule being developed as an investigational treatment for non-alcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. Both of these conditions are…

A new technique to create lung cells from other, more easily accessible cell types could be useful for understanding diseases like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The technique was described in an article, “Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity…

Galapagos NV announced that its Phase 2 PINTA trial, evaluating the safety and effectiveness of oral GLPG1205 in people with idiopathic pulmonary fibrosis (IPF), has completed patient recruitment ahead of schedule. GLPG1205 is a small molecule designed to specifically block the activity of GPR84, a protein that…

Use of INOpulse — inhaled nitric oxide — increased physical activity and improved patient-reported outcomes in people with pulmonary fibrosis (PF) who are at risk of pulmonary hypertension (PH), new topline clinical trial data suggest. INOpulse, developed by Bellerophon Therapeutics, is a device that delivers nitric oxide (NO)…